JP2023541217A5 - - Google Patents
Info
- Publication number
- JP2023541217A5 JP2023541217A5 JP2023501419A JP2023501419A JP2023541217A5 JP 2023541217 A5 JP2023541217 A5 JP 2023541217A5 JP 2023501419 A JP2023501419 A JP 2023501419A JP 2023501419 A JP2023501419 A JP 2023501419A JP 2023541217 A5 JP2023541217 A5 JP 2023541217A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence shown
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026017958A JP2026071342A (ja) | 2020-07-10 | 2026-02-05 | 抗IgE改変抗体及びその適用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010663029 | 2020-07-10 | ||
| CN202010663029.3 | 2020-07-10 | ||
| CN202110750959.7 | 2021-07-01 | ||
| CN202110750959 | 2021-07-01 | ||
| PCT/CN2021/105620 WO2022007965A1 (zh) | 2020-07-10 | 2021-07-09 | 一种抗IgE的工程化抗体及其应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026017958A Division JP2026071342A (ja) | 2020-07-10 | 2026-02-05 | 抗IgE改変抗体及びその適用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541217A JP2023541217A (ja) | 2023-09-29 |
| JP2023541217A5 true JP2023541217A5 (cg-RX-API-DMAC7.html) | 2024-07-17 |
Family
ID=79552269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501419A Ceased JP2023541217A (ja) | 2020-07-10 | 2021-07-09 | 抗IgE改変抗体及びその適用 |
| JP2026017958A Pending JP2026071342A (ja) | 2020-07-10 | 2026-02-05 | 抗IgE改変抗体及びその適用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026017958A Pending JP2026071342A (ja) | 2020-07-10 | 2026-02-05 | 抗IgE改変抗体及びその適用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230250191A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4180454A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023541217A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230042030A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116018352A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021306786A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023000400A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3185192A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299747A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI896700B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022007965A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318098A (en) | 2022-07-01 | 2025-02-01 | Alk Abell? As | IGE-FCER pushers |
| CN116143932B (zh) * | 2022-12-07 | 2025-02-11 | 南开大学 | 一种针对IgE的抗体或其抗原结合片段以及Fc变体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1260521B1 (en) | 1991-08-14 | 2007-11-21 | Genentech Inc. | Immunoglobulin variants for specific Fc epsilon receptors |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| NZ601815A (en) * | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
| US20180273626A1 (en) * | 2015-09-11 | 2018-09-27 | The Board Of Trustees Of The Leland Stanford Junio University | Omalizumab resistant ige variants and their use in anti-ige therapy |
| GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| EP4342541A3 (en) * | 2017-04-07 | 2024-07-03 | Kookmin University Industry Academy Cooperation Foundation | Antibody fc variants for increased blood half-life |
| KR20220098056A (ko) * | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| EP3788078A4 (en) * | 2018-05-04 | 2022-03-02 | Allakos Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA |
-
2021
- 2021-07-09 EP EP21836979.1A patent/EP4180454A4/en active Pending
- 2021-07-09 KR KR1020237003490A patent/KR20230042030A/ko active Pending
- 2021-07-09 CA CA3185192A patent/CA3185192A1/en active Pending
- 2021-07-09 IL IL299747A patent/IL299747A/en unknown
- 2021-07-09 JP JP2023501419A patent/JP2023541217A/ja not_active Ceased
- 2021-07-09 BR BR112023000400A patent/BR112023000400A2/pt unknown
- 2021-07-09 US US18/004,959 patent/US20230250191A1/en active Pending
- 2021-07-09 WO PCT/CN2021/105620 patent/WO2022007965A1/zh not_active Ceased
- 2021-07-09 AU AU2021306786A patent/AU2021306786A1/en active Pending
- 2021-07-09 TW TW110125327A patent/TWI896700B/zh active
- 2021-07-09 CN CN202180049003.2A patent/CN116018352A/zh active Pending
-
2026
- 2026-02-05 JP JP2026017958A patent/JP2026071342A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023075294A (ja) | 抗cd47抗体及びその応用 | |
| CN109963588B (zh) | 抗ctla4抗体 | |
| CN107922503B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| CN112500485B (zh) | 一种抗b7-h3抗体及其应用 | |
| JP7339948B2 (ja) | モノクローナル抗体およびその使用法 | |
| TWI869334B (zh) | 一種lag-3抗體醫藥組成物及其用途 | |
| AU2020213579B2 (en) | Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| CA3082321A1 (en) | Single domain antibodies that bind to cd137 | |
| CN110198739B (zh) | 一种pd-l1抗体药物组合物及其用途 | |
| WO2022166802A1 (zh) | 抗人cd271的单克隆抗体及用途 | |
| TWI914298B (zh) | 特異性結合至人類T細胞受體之TRBV-9家族之β區的單株抗體及其使用之方法 | |
| CN112512550A (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| CN105051067A (zh) | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 | |
| CN107955072A (zh) | Pd-1抗体 | |
| BR122020002414B1 (pt) | Uso de anticorpos anti-cd27 humanos | |
| CN106565840B (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| JP2026071342A5 (cg-RX-API-DMAC7.html) | ||
| TWI865727B (zh) | 一種抗il-4r抗體醫藥組成物及其用途 | |
| JP2023535384A (ja) | 抗pd-1抗体医薬組成物及びその用途 | |
| CN114981301A (zh) | Pd1和vegfr2双结合剂 | |
| CN115715297A (zh) | 抗flt3抗体和组合物 | |
| BR112021010948A2 (pt) | Anticorpos agonistas de flt3 e seus usos | |
| CN111956606A (zh) | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂 | |
| CN116018352A (zh) | 一种抗IgE的工程化抗体及其应用 | |
| BR112021010414A2 (pt) | Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas |